Latest News
& Press Releases

AbbVie shared more positive results for its migraine prevention drug, Qulipta, just three days after FDA approval to expand its label.

The deal could be worth more than $1 billion, starting with an upfront payment of $22.75 million.

Moderna claims it can have vaccines ready for multiple cancer types by 2030, but experts say challenges remain.

The checkpoint inhibitor is approved for several cancers in China, but after an indefinite FDA delay last summer, BeiGene’s partner Novartis still awaits its first U.S. approval.

Abdera Therapeutics will use the money to fund its ROVEr platform and advance its lead asset ABD-147 for small-cell lung cancer.

Polivy is approved for front-line DLBCL as part of a combination regimen including Rituxan, cyclophosphamide, doxorubicin and prednisone.

As companies prioritize in-person work, many have begun to do more to incentivize a reluctant workforce to come into the office.

When a person notifies their employer that they have a disability, the company must make a good-faith effort to adjust to enable the employee to continue in their job.

The leaked data show that Carvykti cuts the risk of disease relapse by 74% versus standard chemotherapy regimens.

Lilly investigators said they hoped to differentiate their Phase I candidate from the competitive KRAS space by making it the first to gain approval as a first-line treatment.

Qulipta’s label expansion makes it the first oral CGRP receptor antagonist approved for episodic and chronic migraine.

The checkpoint inhibitor improved patient outcomes in three cancer trials, according to results presented at the AACR meeting.

• Appointment strengthens medical, regulatory, and commercial leadership as Company prepares to complete early market access regulatory filings in the U.S., U.K, Europe and Australia in anticipation of OST-HER2 approval decisions expected by year-end 2026 • Upcoming FDA Pre-BLA meeting will focus on the use of recent seroconversion biomarker data as a key surrogate clinical efficacy endpoint to support a BLA for OST-HER2 under the Accelerated Approval Program • Commercialization and reimbursement preparations well underway for the U.S., U.K., and Europe in parallel with ongoing partnership discussions

• Quarterly revenue up 8% year over year; Annual revenue guidance range remains at $42-$48 million • CDMO fragrance and Saffron projects reach successful milestones; First quarter CDMO revenue grew 135% YoY • VINIA brand customer base grows to 90,000 active users as of the end of April • Two-lens framework enacted in Q1 to optimize performance across CDMO and D2C businesses

Business development appointment is aligned with securing long-term customers for development and manufacturing partnerships

Another major milestone in its continuous global IP strategy, advancing protection of VIVI Cap Smart across international markets Highlights Granted Patent covers the design of VIVI Cap Smart™ across major international, growing market Strengthens the Company’s intellectual property position in one of the world’s largest healthcare and consumer markets Supports commercialization strategy and strategic discussions with appliance manufacturers Design term extends through May 16, 2039 Company enters into financing arrangement to support inventory build for growing portfolio